| Title |
CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, July 2018
|
| DOI | 10.1007/s00262-018-2202-4 |
| Pubmed ID | |
| Authors |
Hakimeh Ebrahimi-Nik, William L. Corwin, Tatiana Shcheglova, Alok Das Mohapatra, Ion I. Mandoiu, Pramod K. Srivastava |
| Abstract |
Dendritic cells play a critical role in initiating T-cell responses. In spite of this recognition, they have not been used widely as adjuvants, nor is the mechanism of their adjuvanticity fully understood. Here, using a mutated neoepitope of a mouse fibrosarcoma as the antigen, and tumor rejection as the end point, we show that dendritic cells but not macrophages possess superior adjuvanticity. Several types of dendritic cells, such as bone marrow-derived dendritic cells (GM-CSF cultured or FLT3-ligand induced) or monocyte-derived ones, are powerful adjuvants, although GM-CSF-cultured cells show the highest activity. Among these, the CD11c+ MHCIIlo sub-set, distinguishable by a distinct transcriptional profile including a higher expression of heat shock protein receptors CD91 and LOX1, mannose receptors and TLRs, is significantly superior to the CD11c+ MHCIIhi sub-set. Finally, dendritic cells exert their adjuvanticity by acting as both antigen donor cells (i.e., antigen reservoirs) as well as antigen presenting cells. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| United Kingdom | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 23% |
| Student > Bachelor | 5 | 16% |
| Other | 4 | 13% |
| Professor | 2 | 6% |
| Student > Doctoral Student | 2 | 6% |
| Other | 3 | 10% |
| Unknown | 8 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 5 | 16% |
| Biochemistry, Genetics and Molecular Biology | 4 | 13% |
| Engineering | 4 | 13% |
| Medicine and Dentistry | 4 | 13% |
| Agricultural and Biological Sciences | 2 | 6% |
| Other | 0 | 0% |
| Unknown | 12 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2024.
All research outputs
#6,506,177
of 23,923,788 outputs
Outputs from Cancer Immunology, Immunotherapy
#895
of 2,897 outputs
Outputs of similar age
#108,539
of 331,683 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#13
of 47 outputs
Altmetric has tracked 23,923,788 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,897 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,683 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.